![]() The monographs of the European Pharmacopoeia (as amended by Supplements published by the Council of Europe) are reproduced either in the British Pharmacopoeia, or in the associated edition of the British Pharmacopoeia (Veterinary). The British Pharmacopoeia is published on behalf of the Health Ministers of the United Kingdom on the recommendation of the Commission on Human Medicines, in accordance with section 99(6) of the Medicines Act 1968, and notified in draft to the European Commission (EC) in accordance with Directive 98/34/EEC. Inclusion of a substance in a pharmacopoeia does not indicate that it is either safe or effective for the treatment of any disease. Pharmacopoeial standards are compliance requirements that is, they provide the means for an independent judgement as to the overall quality of an article, and apply throughout the shelf-life of a product. Together with the British National Formulary (BNF), the British Pharmacopoeia defines the UK's pharmaceutical standards. The British Pharmacopoeia is an important statutory component in the control of medicines, which complements and assists the licensing and inspection processes of the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Pharmacopoeial standards are publicly available and legally enforceable standards of quality for medicinal products and their constituents. It is an annually published collection of quality standards for medicinal substances in the UK, which is used by individuals and organisations involved in pharmaceutical research, development, manufacture and testing. The British Pharmacopoeia ( BP) is the national pharmacopoeia of the United Kingdom. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |